Emerging markets will drive demerged Abbott DMP business
This article was originally published in Clinica
Executive Summary
With already 70% of its sales in markets outside the US, Abbott expects to grow the proposed diversified medical products company by further increasing its exposure in fast growing emerging markets from 40% to nearly 50% by 2015.